Integrating breast cancer genetics into clinical practice

Women's Health

Volumn 8, Issue 1, 2012, Pages 99-112

  Mukherjee, Abhik ^a   Rakha, Emad A ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

breast cancer; genetics; genomics; management; outcome

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DASATINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RIDAFOROLIMUS; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; TYKREB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOMICS; HER2 GENE; HUMAN; ONCOGENE; PREDICTIVE VALUE; PROGNOSIS; RADIATION RESPONSE; REVIEW; STRATIFICATION; TAXONOMY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME, HUMAN; HUMANS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PROGNOSIS;

EID: 83755180433     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.81     Document Type: Review

References (106)

1. Koeffler HP, McCormick F, Denny C. Molecular mechanisms of cancer. West. J. Med. 155(5), 505-514 (1991).
2. Canman CE, Kastan MB. Induction of apoptosis by tumor suppressor genes and oncogenes. Semin. Cancer Biol. 6(1), 17-25 (1995).
3. Sausville EA. The challenge of pathway and environment-mediated drug resistance. Cancer Metastasis Rev. 20(1-2), 117-122 (2001). (Pubitemid 34074687)
4. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer 7(7), 545-553 (2007). (Pubitemid 46985399)
5. Stokstad E. DNA testing. Genetic screen misses mutations in women at high risk of breast cancer. Science 311(5769), 1847 (2006).
6. Pollack JR, Sorlie T, Perou CM et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl Acad. Sci. USA 99(20), 12963-12968 (2002).
7. Reyal F, Rouzier R, Depont-Hazelzet B et al. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One 6(5), e20297 (2011).
8. Rakha EA, Reis-Filho JS, Baehner F et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 12(4), 207 (2010).
9. Abba MC, Sun H, Hawkins KA et al. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol. Cancer Res. 5(9), 881-890 (2007). (Pubitemid 47416665)
10. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 88(20), 1456-1466 (1996). (Pubitemid 26340047)
11. Van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452(7187), 564-570 (2008). (Pubitemid 351483370)
12. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006). (Pubitemid 46622311)
13. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 406(6797), 747-752 (2000).
14. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001). (Pubitemid 32878711)
15. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003). (Pubitemid 36842560)
16. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004). (Pubitemid 40051905)
17. Van't Veer LJ, Dai H, Van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002). (Pubitemid 34130608)
18. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98(4), 262-272 (2006). (Pubitemid 43264710)
19. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10(4), R65 (2008).
20. Buyse M, Loi S, Van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98(17), 1183-1192 (2006). (Pubitemid 44390989)
21. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28(11), 1829-1834 (2010).
22. Hall DA, Ptacek J, Snyder M. Protein microarray technology. Mech. Ageing Dev. 128(1), 161-167 (2007). (Pubitemid 46073070)
23. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer 116(3), 340-350 (2005). (Pubitemid 40993329)
24. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790-800 (2009).
25. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J. Clin. Oncol. 26(15), 2568-2581 (2008).
26. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21), 2492-2502 (2006). (Pubitemid 43854964)
27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER2/neu-overexpressing phenotypes. Hum. Pathol. 37(9), 1217-1226 (2006). (Pubitemid 44286991)
28. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res. Treat. 120(2), 293-308 (2010).
29. Cuzick J, Dowsett M, Pineda S et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J. Clin. Oncol. 29(32), 4273-4278 (2011).
30. Van de Vijver MJ, He YD, Van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002). (Pubitemid 35461656)
31. Kelly CM, Krishnamurthy S, Bianchini G et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22), 5161-5167 (2010).
32. Marchionni L, Wilson RF, Wolff AC et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann. Intern. Med. 148(5), 358-369 (2008). (Pubitemid 351665467)
33. Goetz MP, Suman VJ, Ingle JN et al. A two-gene expression ratio of homeobox 13 and interleukin 17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res. 12(7 Pt 1), 2080-2087 (2006)
34. Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6), 607-616 (2004). (Pubitemid 38748922)
35. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460), 671-679 (2005). (Pubitemid 40260888)
36. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356(3), 217-226 (2007). (Pubitemid 46143225)
37. Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102(10), 3738-3743 (2005). (Pubitemid 40354681)
38. Chi JT, Wang Z, Nuyten DS et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3(3), e47 (2006).
39. Ahr A, Holtrich U, Solbach C et al. Molecular classification of breast cancer patients by gene expression profiling. J. Pathol. 195(3), 312-320 (2001).
40. Naoi Y, Kishi K, Tanei T et al. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res. Treat. 128(3), 633-641 (2011).
41. Jerevall PL, Ma XJ, Li H et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br. J. Cancer 104(11), 1762-1769 (2011).
42. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006).
43. Chang JC, Makris A, Gutierrez MC et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res. Treat. 108(2), 233-240 (2008). (Pubitemid 351311356)
44. Ma XJ, Salunga R, Dahiya S et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 14(9), 2601-2608 (2008).
45. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8(8), R157 (2007).
46. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14(16), 5158-5165 (2008).
47. Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14(5), 518-527 (2008). (Pubitemid 351655218)
48. Gravier E, Pierron G, Vincent-Salomon A et al. A prognostic DNA signature for T1T2 node-negative breast cancer patients. Genes Chromosomes Cancer 49(12), 1125-1134 (2010).
49. Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat. Rev. Clin. Oncol. 7(12), 725-732 (2010).
50. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11(1), 55-65 (2010).
51. Jacquemier J, Ginestier C, Rougemont J et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 65(3), 767-779 (2005). (Pubitemid 40216434)
52. Cobleigh MA, Tabesh B, Bitterman P et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res. 11(24 Pt 1), 8623-8631 (2005). (Pubitemid 43005909)
53. Toi M, Iwata H, Yamanaka T et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 116(13), 3112-3118 (2010).
54. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Gene Expression Profiling in Women with Lymph- Node-Positive Breast Cancer to Select Adjuvant Chemotherapy Treatment. Blue Cross and Blue Shield Association, Chicago, IL, USA (2010).
55. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Gene Expression Profiling for Managing Breast Cancer Treatment. Blue Cross and Blue Shield Association, Chicago, IL, USA, 22 (2008).
56. ECRI Institute. Gene Expression Profiling of Breast Cancer to Predict the Likelihood of Recurrence. Emerging technology evidence report. ECRI Institute, PA, USA (2008).
57. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet. Med. 11(1), 66-73 (2009).
58. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26(5), 721-728 (2008). (Pubitemid 351264384)
59. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26(5), 729-735 (2008). (Pubitemid 351264385)
60. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005). (Pubitemid 40559006)
61. Verhoog LC, Brekelmans CT, Seynaeve C et al. Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351(9099), 316-321 (1998). (Pubitemid 28052696)
62. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66(16), 8109-8115 (2006). (Pubitemid 44299177)
63. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
64. Sirohi B, Arnedos M, Popat S et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol. 19(11), 1847-1852 (2008).
65. Fourquet A, Stoppa-Lyonnet D, Kirova YM, Sigal-Zafrani B, Asselain B. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am. J. Clin. Oncol. 32(2), 127-131 (2009).
66. Rottenberg S, Nygren AO, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl Acad. Sci. USA 104(29), 12117-12122 (2007). (Pubitemid 47185639)
67. Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11(14), 5175-5180 (2005). (Pubitemid 41003703)
68. Collins LC, Martyniak A, Kandel MJ et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am. J. Surg. Pathol. 33(7), 1093-1097 (2009).
69. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737), 235-244 (2010).
70. Pfeifer GP, Hainaut P. Next-generation sequencing: emerging lessons on the origins of human cancer. Curr. Opin. Oncol. 23(1), 62-68 (2010).
71. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-1093 (2007). (Pubitemid 47014426)
72. Castro NP, Osorio CA, Torres C et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res. 10(5), R87 (2008).
73. Schuetz CS, Bonin M, Clare SE et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res. 66(10), 5278-5286 (2006). (Pubitemid 43844952)
74. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res. Treat. 76(1), 27-36 (2002). (Pubitemid 35178626)
75. Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Ann. Rev. Med. 62, 281-293 (2011).
76. Rakha EA, El-Sayed ME, Green AR et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J. Clin. Oncol. 25(30), 4772-4778 (2007). (Pubitemid 350086480)
77. Habashy HO, Powe DG, Glaab E et al. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. Breast Cancer Res. Treat. 128(2), 315-326 (2010).
78. Habashy HO, Powe DG, Rakha EA et al. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur. J. Cancer 44(11), 1541-1551 (2008).
79. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200(3), 290-297 (2003). (Pubitemid 36827302)
80. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229(4717), 974-976 (1985). (Pubitemid 16248488)
81. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007). (Pubitemid 350003059)
82. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987). (Pubitemid 17231334)
83. Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution. Patholog. Res. Int. 2011, 903202 (2011).
84. Mukherjee A, Dhadda AS, Shehata M, Chan S. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin. Pharmacother. 8(13), 2189-2204 (2007). (Pubitemid 47505592)
85. Saal LH, Holm K, Maurer M et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65(7), 2554-2559 (2005). (Pubitemid 40490050)
86. Johnston SR. Are we missing the mTOR target in breast cancer? Breast Cancer Res. Treat. 128(3), 607-611 (2011).
87. Margariti N, Fox SB, Bottini A, Generali D. 'Overcoming breast cancer drug resistance with mTOR inhibitors'. Could it be a myth or a real possibility in the short-term future? Breast Cancer Res. Treat. 128(3), 599-606 (2011).
88. Noh WC, Mondesire WH, Peng J et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 10(3), 1013-1023 (2004). (Pubitemid 38198903)
89. Kurebayashi J, Okubo S, Yamamoto Y, Sonoo H. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 11(1), 38-41 (2004).
90. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res. Treat. 71(1), 67-75 (2002). (Pubitemid 34121818)
91. Reis-Filho JS, Pinheiro C, Lambros MB et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 209(4), 445-453 (2006). (Pubitemid 44194559)
92. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr. Relat. Cancer 12(Suppl. 1), S135-S144 (2005). (Pubitemid 41395421)
93. Smith IE, Walsh G, Skene A et al. A Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 25(25), 3816-3822 (2007). (Pubitemid 47477255)
94. Finn RS, Press MF, Dering J et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J. Clin. Oncol. 27(24), 3908-3915 (2009).
95. Eppenberger U, Kueng W, Schlaeppi JM et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J. Clin. Oncol. 16(9), 3129-3136 (1998). (Pubitemid 28417436)
96. Hochgrafe F, Zhang L, O'Toole SA et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res. 70(22), 9391-9401 (2010).
97. Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B. HDAC inhibitor SNDX-275 induces apoptosis in erbB2- overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res. 69(21), 8403-8411 (2009).
98. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24(29), 4609-4623 (2005). (Pubitemid 41032599)
99. Martin M, Romero A, Cheang MC et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res. Treat. 128(1), 127-136 (2011).
100. Burgess DJ, Doles J, Zender L et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl Acad. Sci. USA 105(26), 9053-9058 (2008).
101. Desmedt C, Di Leo A, de Azambuja E et al. Multifactorial approach to predicting resistance to anthracyclines. J. Clin. Oncol. 29(12), 1578-1586 (2011).
102. Oakman C, Moretti E, Di Leo A. Researching anthracycline therapy. Breast Cancer Res. Treat. 123(1), 171-175 (2010).
103. Farmer P, Bonnefoi H, Anderle P et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15(1), 68-74 (2009).
104. Bonnefoi H, Potti A, Delorenzi M et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: A substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 8(12), 1071-1078 (2007). (Pubitemid 350182953)
105. Eschrich S, Zhang H, Zhao H et al. Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int. J. Radiat. Oncol. Biol. Phys. 75(2), 497-505 (2009).
106. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20(8), 1319-1329 (2009).